Uno studio per valutare gli eventi avversi e l'efficacia di endovenoso (IV) di telisotuzumab adizutecan in combinazione con ossaliplatino IV, fluorocile, acido folinico/leucovorin, bevacizumab, panitumumab in partecipanti agli adulti con carcinoma metastatico coloratottale (AndroMETa-CRC)
Uno studio di protocollo principale di fase 2, etichetta aperta, randomizzato, per valutare la sicurezza e l'efficacia di combinazioni di trattamenti multipli con telisotuzumab adizutecan in soggetti con carcinoma del colon-retto metastatico
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab.
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: ABBVIE CALL CENTER
- Numero di telefono: 844-663-3742
- Email: abbvieclinicaltrials@abbvie.com
Luoghi di studio
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2109
- Reclutamento
- Macquarie University /ID# 271514
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Reclutamento
- Mater Misericordiae /ID# 270694
-
Contatto:
- Site Coordinator
- Numero di telefono: +61731632341
-
-
South Australia
-
Woodville South, South Australia, Australia, 5011
- Reclutamento
- The Queen Elizabeth Hospital /ID# 270693
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Reclutamento
- Austin Health /ID# 270692
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Reclutamento
- One Clinical Research /ID# 270695
-
-
-
-
-
Salzburg, Austria, 5020
- Reclutamento
- Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 268874
-
Vienna, Austria, 1090
- Reclutamento
- Medizinische Universitaet Wien /ID# 268872
-
-
Styria
-
Graz, Styria, Austria, 8010
- Reclutamento
- Medizinische Universitaet Graz /ID# 268876
-
-
-
-
-
São Paulo, Brasile, 04014-002
- Reclutamento
- Nucleo De Pesquisa Clinica Da Rede Sao Camilo /ID# 272311
-
São Paulo, Brasile, 01401-002
- Reclutamento
- Instituto D Or De Pesquisa E Ensino - Regional Sao Paulo /ID# 270546
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasile, 41253-190
- Reclutamento
- Hospital Sao Rafael /ID# 271681
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brasile, 98700-000
- Reclutamento
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 270147
-
-
São Paulo
-
Barretos, São Paulo, Brasile, 14784-400
- Reclutamento
- Hospital De Amor /ID# 271874
-
São José do Rio Preto, São Paulo, Brasile, 15090-000
- Reclutamento
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 271651
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Reclutamento
- Arthur J.E Child Comprehensive Cancer Centre /ID# 269809
-
Edmonton, Alberta, Canada, T6G 1Z2
- Reclutamento
- Cross Cancer Institute. /ID# 272711
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Reclutamento
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270680
-
Toronto, Ontario, Canada, M5G 2M9
- Reclutamento
- Princess Margaret Cancer Centre /ID# 268715
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- Reclutamento
- Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 271368
-
-
-
-
-
Brno, Cechia, 656 53
- Reclutamento
- Masarykuv onkologicky ustav v Brne /ID# 268779
-
Hradec Králové, Cechia, 500 05
- Reclutamento
- Fakultni nemocnice Hradec Kralove - Sokolska /ID# 268773
-
-
Praha 17
-
Prague, Praha 17, Cechia, 128 00
- Reclutamento
- Vseobecna Fakultni nemocnice v Praze /ID# 268775
-
-
Praha 5
-
Prague, Praha 5, Cechia, 150 06
- Reclutamento
- Fakultni nemocnice Motol a Homolka /ID# 268776
-
-
Praha, Hlavni Mesto
-
Prague, Praha, Hlavni Mesto, Cechia, 140 59
- Reclutamento
- Fakultni Thomayerova nemocnice /ID# 269632
-
-
-
-
-
Paris, Francia, 75015
- Reclutamento
- Hopital Europeen Georges Pompidou /ID# 270224
-
-
Hauts-de-France
-
Lille, Hauts-de-France, Francia, 59037
- Reclutamento
- Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez /ID# 270222
-
-
New Aquitaine
-
Poitiers, New Aquitaine, Francia, 86021
- Reclutamento
- Centre Hospitalier Universitaire de Poitiers /ID# 270225
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, Francia, 44000
- Reclutamento
- Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 270221
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Francia, 75013
- Reclutamento
- Hopital Pitie Salpetriere /ID# 270220
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Giappone, 464-8681
- Reclutamento
- Aichi Cancer Center /ID# 270113
-
-
Chiba
-
Kashiwa-shi, Chiba, Giappone, 277-8577
- Reclutamento
- National Cancer Center Hospital East /ID# 270114
-
-
Kanagawa
-
Kawasaki-shi, Kanagawa, Giappone, 216-8511
- Reclutamento
- St Marianna University School Of Medicine /ID# 270111
-
-
Miyagi
-
Sendai, Miyagi, Giappone, 980-8574
- Reclutamento
- Tohoku University Hospital /ID# 270966
-
-
Tokyo
-
Chuo-Ku, Tokyo, Giappone, 104-0045
- Reclutamento
- National Cancer Center Hospital /ID# 270112
-
-
-
-
-
Thessaloniki, Grecia, 54639
- Reclutamento
- Theagenio Cancer Hospital /ID# 269640
-
-
Attica
-
Chaïdári, Attica, Grecia, 12462
- Reclutamento
- University General Hospital Attikon /ID# 268555
-
Nea Kifissia, Attica, Grecia, 14564
- Reclutamento
- General Oncology Hospital of Kifisia Agioi Anargyroi /ID# 268762
-
Piraeus, Attica, Grecia, 18547
- Reclutamento
- Metropolitan Hospital /ID# 269636
-
-
Thessaloniki
-
Panórama, Thessaloniki, Grecia, 55236
- Reclutamento
- St. Luke's Hospital /ID# 269963
-
-
-
-
-
Haifa, Israele, 3109601
- Reclutamento
- Rambam Health Care Campus- Haifa /ID# 268006
-
Jerusalem, Israele, 9103102
- Reclutamento
- Shaare Zedek Medical Center /ID# 268009
-
Jerusalem, Israele, 91120
- Reclutamento
- Hadassah Medical Center-Hebrew University /ID# 268007
-
-
Central District
-
Petah Tikva, Central District, Israele, 4941492
- Reclutamento
- Rabin Medical Center. /ID# 268008
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, Israele, 6423906
- Reclutamento
- Tel Aviv Sourasky Medical Center /ID# 268010
-
-
-
-
Milano
-
Milan, Milano, Italia, 20162
- Reclutamento
- ASST Grande Ospedale Metropolitano Niguarda /ID# 269142
-
Contatto:
- Site Coordinator
- Email: ctu.oncologia@ospedaleniguarda.it
-
-
Napoli
-
Naples, Napoli, Italia, 80138
- Reclutamento
- Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 269191
-
-
-
-
-
Rio Piedras, Porto Rico, 00935
- Reclutamento
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268809
-
San Juan, Porto Rico, 00917-5022
- Reclutamento
- Puerto Rico Medical Research Center /ID# 268825
-
-
-
-
-
Manchester, Regno Unito, M20 4BX
- Reclutamento
- The Christie NHS Foundation Trust - Christie Hospital /ID# 271561
-
-
Greater London
-
London, Greater London, Regno Unito, E1 2ES
- Reclutamento
- Barts Health NHS Trust /ID# 271189
-
-
Oxfordshire
-
Oxford, Oxfordshire, Regno Unito, OX3 9DU
- Reclutamento
- Oxford University Hospitals Nhs Foundation Trust /ID# 272486
-
-
Surrey
-
Sutton, Surrey, Regno Unito, SM2 5PT
- Reclutamento
- The Royal Marsden - Sutton /ID# 271172
-
-
West Midlands
-
Birmingham, West Midlands, Regno Unito, B9 5SS
- Reclutamento
- Heartlands Hospital - University Hospitals Birmingham /ID# 271178
-
-
-
-
-
Barcelona, Spagna, 08035
- Reclutamento
- Hospital Universitario Vall de Hebron /ID# 270191
-
Madrid, Spagna, 28027
- Reclutamento
- Clinica Universidad de Navarra - Madrid /ID# 269754
-
Madrid, Spagna, 28046
- Reclutamento
- Hospital Universitario La Paz /ID# 269730
-
Valencia, Spagna, 46010
- Reclutamento
- Hospital Clinico Universitario de Valencia /ID# 269805
-
-
Cantabria
-
Santander, Cantabria, Spagna, 39008
- Reclutamento
- Hospital Universitario Marques de Valdecilla /ID# 269732
-
-
Navarre
-
Pamplona, Navarre, Spagna, 31008
- Reclutamento
- Clinica Universidad de Navarra - Pamplona /ID# 269753
-
-
-
-
California
-
Duarte, California, Stati Uniti, 91010
- Reclutamento
- City of Hope National Medical Center /ID# 270255
-
Santa Monica, California, Stati Uniti, 90404
- Reclutamento
- UCLA - Santa Monica /ID# 270621
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06510
- Reclutamento
- Yale New Haven Hospital /ID# 270565
-
-
Florida
-
Orlando, Florida, Stati Uniti, 32803
- Reclutamento
- AdventHealth Orlando /ID# 270789
-
-
Georgia
-
Marietta, Georgia, Stati Uniti, 30060
- Reclutamento
- Northwest Georgia Oncology Centers /ID# 270245
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- Reclutamento
- University of Chicago Medical Center /ID# 271688
-
Hinsdale, Illinois, Stati Uniti, 60521
- Reclutamento
- Hope And Healing Cancer Services /ID# 271562
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Dana-Farber Cancer Institute /ID# 270624
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109-5000
- Reclutamento
- University Of Michigan /ID# 270790
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64111
- Reclutamento
- Saint Lukes Hospital of Kansas City /ID# 270633
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68130
- Reclutamento
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27514
- Reclutamento
- University of North Carolina at Chapel Hill /ID# 267786
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45245
- Reclutamento
- Oncology Hematology Care - Eastgate /ID# 271493
-
-
Texas
-
Austin, Texas, Stati Uniti, 78705
- Reclutamento
- Texas Oncology - Austin Midtown /ID# 271354
-
Webster, Texas, Stati Uniti, 77598
- Reclutamento
- Texas Oncology - Deke Slayton Cancer Center /ID# 271355
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- Virginia Cancer Specialists - Fairfax /ID# 271351
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Reclutamento
- University Of Washington /ID# 271298
-
-
-
-
-
Kaohsiung City, Taiwan, 807
- Reclutamento
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 269724
-
Kaohsiung City, Taiwan, 833
- Reclutamento
- Kaohsiung Chang Gung Memorial Hospital /ID# 269726
-
Tainan, Taiwan, 704
- Reclutamento
- National Cheng Kung University Hospital /ID# 270835
-
Taipei, Taiwan, 112
- Reclutamento
- Taipei Veterans General Hospital /ID# 269718
-
Taipei, Taiwan, 100
- Reclutamento
- National Taiwan University Hospital /ID# 269717
-
Taoyuan City, Taiwan, 333
- Reclutamento
- Linkou Chang Gung Memorial Hospital /ID# 269725
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Laboratory values meeting the criteria within the protocol.
- Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
Exclusion Criteria:
- Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
- History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Substudy 1: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Sperimentale: Substudy 1: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Sperimentale: Substudy 1: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecandetermined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Sperimentale: Substudy 1: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Sperimentale: Substudy 2: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil (5-FU) and leucovorin (LV) and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Sperimentale: Substudy 2: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Sperimentale: Substudy 2: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Sperimentale: Substudy 2: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and panitumumab as part of the approximately 6 year study duration. |
IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection IV Infusion |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1.
Lasso di tempo: Up to 24 Weeks
|
OR is defined as confirmed CR or PR as assessed by the investigator per RECIST, version 1.1. |
Up to 24 Weeks
|
|
Number of Participants with Adverse Events (AE)s
Lasso di tempo: Up to Approximately 6 Years
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 6 Years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-Free Survival (PFS) as Assessed by the Investigator
Lasso di tempo: Up to 22 Months
|
PFS is defined as the time from the first dose of study treatment to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by the investigator or death from any cause, whichever occurs earlier. |
Up to 22 Months
|
|
Duration of Response (DOR) as Assessed by the investigator
Lasso di tempo: Up to 14 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by the investigator or death from any cause, whichever occurs first. |
Up to 14 Months
|
|
Overall Survival (OS)
Lasso di tempo: Up to Approximately 6 Years
|
OS is defined as the time from first dose of study treatment to the event of death from any cause. |
Up to Approximately 6 Years
|
|
Disease Control (DC) as Assessed by the Investigator
Lasso di tempo: Up to Approximately 6 Years
|
DC is defined as best overall response of confirmed CR or confirmed PR, or stable disease (SD) based on RECIST, version 1.1 as determined by the investigator. |
Up to Approximately 6 Years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: ABBVIE INC., AbbVie
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie intestinali
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Neoplasie intestinali
- Malattie del retto
- Malattie del colon
- Neoplasie colorettali
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Enzimi e coenzimi
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Complessi di coordinamento
- Pirimidine
- Formyltetraidrofolates
- Tetraidrofolati
- Acido folico
- Pterins
- Pteridine
- Uracile
- Pirimidinoni
- Coenzimi
- Oxaliplatino
- Bevacizumab
- Panitumumab
- Fluorouracile
- Leucovorina
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- M24-533
- EU CT (Altro identificatore: 2024-512981-33-00)
- 2024-512981-33-00 (Ctis)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Periodo di condivisione IPD
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Criteri di accesso alla condivisione IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .